Biomedical launches X-Pure® GelDAT®, first ever purified and phenol-functionalized gelatin
Irving, Texas, May 20th, 2021 – Rousselot, a brand of Darling Ingredients, and the global leader of collagen-based solutions1 expands its range of purified, medical grade, modified gelatins with the launch of X-Pure GelDAT – Gelatin Desaminotyrosine. Created in response to customer’s demand to overcome the barriers encountered in clinic translation, this is the first, readily available biomaterial of its kind. X-Pure GelDAT offers guaranteed purity and consistency at scale, vital to the successful development of biomedical applications used in the human body.
X-Pure GelDAT - A powerful alternative to GelTYR
Until now, one of the go-to products for researchers requiring a biomaterial more adhesive than GelMA - Gelatin Methacryloyl, was GelTYR - Gelatin Tyramine. However, GelTYR has several limitations, most notably its irreproducibility and the lack of a scalable production process. The chemical reactions required to make GelTYR lead to uncontrollable side reactions, which can significantly delay product development and negatively impact the likelihood of success.
Dr. Jeff Daelman, Business Development Manager at Rousselot Biomedical said, “Based on our extensive experience and scientific expertise in modified gelatins, we created a versatile, effective and scalable alternative to GelTYR. Rousselot Biomedical delivered a tailored X-Pure GelDAT solution, from customer’s initial briefing into pre-clinical trials in less than a year!”
Customization and consistency
Rousselot’s proprietary, scalable process means products with customized functionalities can be produced in a standardized, purified, traceable and consistent manner. Rousselot offers the best of both worlds: a customized yet consistent product on which both researchers and large pharmaceutical manufacturers can rely.
“Rousselot’s X-Pure GelDAT’s research grade is functionally equivalent to the GMP grade material, so researchers have less risk of having to re-validate their biomaterial prior to clinical trials. Compromising on quality in early research can also cause significant scale-up issues and delays in preparation for clinical trials. X-Pure GelDAT can be used throughout every development phase,” said Dr. Daelman.
Unique adhesive properties for a range of specific biomedical applications
New X-Pure GelDAT is a unique addition to the Rousselot portfolio because of its phenolic modification that grants superior adhesion properties to human tissues and because it can be cross-linked by both enzymatic reaction or photo-induction. These characteristics allow its combination with other biomaterials for the creation of more versatile and complex structures for drug delivery, tissue engineering, organ-on-a-chip and complex wound dressing applications
Dr. Daelman concluded, “This is an exciting time for the biomedical sector as highly purified and reliable gelatin-based materials unlock the potential for new innovations. We are excited to collaborate with customers and to jointly develop new gelatin-based solutions, that have a positive impact in these promising fields of research. We will be sharing more insights and information during this year’s BIO Digital 2021.”
1Collagen, Market estimates and trend analysis, 2022 Grand View Research.